NEW YORK, Oct. 27 (GenomeWeb News) - Sirna Therapeutics has signed on to manufacture for Archemix the antithrombin aptamer ARC183, the companies said today.
ARC183 is Archemix's first drug development candidate and is being tested for use as an anti-coagulant/anti-thrombotic in coronary artery bypass graft surgery. Under their arrangement, Sirna will make and supply Archemix with the agent for use in its development efforts through phase IIa clinical trials.
"This collaboration is consistent with our strategy of forming process development and manufacturing agreements ... to generate revenues and maintain our leadership in the nucleic acid chemistry field," Sirna president and CEO Howard Robin said in a statement.
Specific terms of the deal were not disclosed.